GlobeNewswire Inc.··Glancy Prongay Wolke & Rotter LlpNektar Therapeutics Hit With Securities Fraud Lawsuit Over Failed Alopecia Trial
Nektar Therapeutics ($NKTR) faces securities fraud lawsuit after Phase 2b alopecia trial failed due to enrollment violations, triggering 7.8% stock decline.
NKTRsecurities fraudclass action lawsuit